Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099983 · ClinicalTrials.gov registry record · Phase 2
Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder
A Phase 2 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 2
- Development phase
- 296
- Enrollment target
NCT00099983 is a Phase 2 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 296 participants.
The verdict
NCT00099983, a Phase 2 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 296 participants
- Enrollment target
Study Summary
The purpose of this research of 400 participants is to determine whether a drug called risperidone can decrease symptoms of Post-Traumatic Stress Disorder (PTSD). It is a placebo-controlled study, meaning that half of the participants will be assigned to receive a pill that contains no drug. The treatment phase of the study will last for 6 months, during which time participants will continue to receive all their usual treatments in addition to the study treatment and will be asked to complete procedures and assessments (questionnaires, interviews, laboratory tests, physical exams, etc.) related to their PTSD symptoms at various points within the 6-month treatment phase. At the end of the 6-month study, participants will discontinue the study treatment.
Interventions
- DRUG Placebo
- DRUG Risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2006-10 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099983
The ClinicalTrials.gov registry entry for NCT00099983 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00099983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099983 about?
NCT00099983 is a clinical study titled "Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder". The purpose of this research of 400 participants is to determine whether a drug called risperidone can decrease symptoms of Post-Traumatic Stress Disorder (PTSD). It is a placebo-controlled study, meaning that half of the participants will be assigned to receive a pill that contains no drug. The tre...
What is the current status of trial NCT00099983?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 296 participants. The study started on 2006-10. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00099983?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG).
Who is sponsoring clinical trial NCT00099983?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.